Body-worn subcutaneous drug delivery systems for large-volume therapeutics
Enable manufactures wearable drug delivery devices (enFuse®) that administer 5–25mL drugs subcutaneously, targeting improved patient convenience and healthcare economics. The hiring mix is heavily skewed toward manufacturing (7 roles) and engineering (3), with active focus on compliance implementation (ISO 13485, CFR 820, MDR) and cleanroom qualification—indicating a company scaling production while navigating the regulatory overhead of combination-product approval.
Enable Injections designs and manufactures body-worn infusion systems for subcutaneous administration of large-volume drugs. Founded in 2010 and headquartered in Cincinnati, the company serves pharmaceutical partners seeking alternatives to traditional intravenous or intramuscular delivery. The enFuse® system has received regulatory approval in multiple markets, including a combination-product authorization in the U.S. Manufacturing and operations span cleanroom facilities, sterilization processes (gamma sterilization), and quality systems tied to medical device and pharmaceutical regulations.
Enable makes enFuse®, a wearable device that delivers large-volume (5–25mL) drugs via subcutaneous injection. The system aims to improve patient convenience and safety outcomes for therapeutics that would otherwise require IV or IM administration.
Cincinnati, Ohio. The company was founded in 2010 and is privately held, with 201–500 employees.
Other companies in the same industry, closest in size